Metagenomi Therapeutics, Inc.
No enriched coverage for $MGX in the last 7 days.
No SEC Form 4 filings for $MGX in the last 30 days.
See all $MGX insider activity →BlackRock-backed consortium including Abu Dhabi’s MGX and the Artificial Intelligence Infrastructure Partnership committed $5bn to expand Aligned Data Centres after closing its acquisition. Aligned was bought from Macquarie Asset Management and co-investors at a $40bn enterprise value. Aligned operates 51 campuses and 6.4GW capacity, with HQ in Dallas.
Reuters reports a BlackRock-backed consortium with Abu Dhabi’s MGX committed an additional $5 billion of growth capital to Aligned Data Centers after closing its $40 billion acquisition. The group, buying from Macquarie Asset Management, plans $30 billion of equity initially, potentially up to $100 billion including debt, to expand AI computing capacity.
Australia’s S&P/ASX 200 rose modestly, up 0.13% to 8,797.7 points by midday, after early gains. Brent crude climbed 3.1% to $91.07 on US-Iran escalation, lifting Viva Energy, Deep Yellow, Karoon, Woodside and Ampol. Semiconductor losses followed Moonshot’s Kimi K3 release; TSMC fell 7.3% and ASX tech/gold names also dropped.
Recent MGX coverage spans financial news, mergers & acquisitions and market movers.
No tradable ticker identified for MGX because it is private in the article.
MGX is a named deal participant, but the article does not provide a tradable public ticker context.
MGX has a concrete divestiture headline that can affect asset valuation and capital allocation expectations.
Potential acquisition talks could shift MGX’s capital allocation and expansion path, but deal terms/timing remain uncertain.
Board turnover and director elections are typically low-to-moderate signal events; absent stated disagreement, near-term impact is likely limited but can affect governance perception and committee composition.
alphai scores every news story that mentions MGX with an AI model for sentiment and relevance, and aggregates insider trades from Metagenomi Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BlackRock-backed consortium including Abu Dhabi’s MGX and the Artificial Intelligence Infrastructure Partnership committed $5bn to expand Aligned Data Centres after closing its acquisition. Aligned was bought from Macquarie Asset Management and co-investors at a $40bn enterprise value. Aligned operates 51 campuses and 6.4GW capacity, with HQ in Dallas.
4 min readReuters reports a BlackRock-backed consortium with Abu Dhabi’s MGX committed an additional $5 billion of growth capital to Aligned Data Centers after closing its $40 billion acquisition. The group, buying from Macquarie Asset Management, plans $30 billion of equity initially, potentially up to $100 billion including debt, to expand AI computing capacity.
3 min readAustralia’s S&P/ASX 200 rose modestly, up 0.13% to 8,797.7 points by midday, after early gains. Brent crude climbed 3.1% to $91.07 on US-Iran escalation, lifting Viva Energy, Deep Yellow, Karoon, Woodside and Ampol. Semiconductor losses followed Moonshot’s Kimi K3 release; TSMC fell 7.3% and ASX tech/gold names also dropped.
7 min readMGX, an Abu Dhabi-backed AI investor, is exploring a multi-billion acquisition of Singapore-based data centre operator DayOne, three sources said. MGX has worked with an investment bank on the potential deal. DayOne plans a US IPO targeting a $20bn valuation, which MGX may not match; talks may not lead to a deal. DayOne is affiliated with GDS Holdings.
3 min readMetagenomi Therapeutics, Inc. (MGX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001785279 false 0001785279 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 09,
2 min readMetagenomi reported strong Q1 2026 financial results, with cash reserves of $140.2 million expected to fund operations through Q4 2027. The company advanced its MGX-001 hemophilia A program towards a late-2026 regulatory filing and 2027 trial initiation, while also showcasing in vivo proof-of-concept for its gene integration system and a compact CRISPR nuclease. Despite a decline in collaboration revenue, the company reduced R&D and G&A expenses, reinforcing its commitment to internally driven, potentially curative genetic treatments.
3 min readMetagenomi, Inc. ( NASDAQ:MGX ) on Tuesday shared new dose range finding data from its MGX-001 hemophilia A program. The data demonstrated curative factor VIII ( FVIII ) activity in non-human primates ( NHPs ) and informs a clinical dose regimen strategy.
4 min readMetagenomi (MGX) delivered earnings and revenue surprises of +8.33% and -6.44%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readDoes Metagenomi (MGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 min readMetagenomi (MGX) delivered earnings and revenue surprises of +20.59% and +20.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
2 min read
